Elisabetta Bonzano MD, PhD· @to_be_elizabeth · X·· 1 天前评分70
正文 · 机器翻译
📌 postMONARCH III期试验总生存期结果：abemaciclib + fulvestrant 对比 placebo + fulvestrant，用于既往 CDK4/6 抑制剂 + 内分泌治疗后进展的 HR+、HER2- 晚期乳腺癌
@KalinskyKevin
#ESMO26 🇪🇸 @OncoAlert #OncoAlertAF
108 浏览 · 4 赞 · 3 转发 · 0 回复
会议摘要
1RO按 Rapid oral 1: Breast cancer, advanced stage 对上
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.org来源：Elisabetta Bonzano MD, PhD · x.com